The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
With the widespread take-up of 3D TV, nut just now in cinema but currently being brought into mainstream TV, I think 2010 is realistic for achievement of target. The fact this share has doubled in value in the first week of 2010 is testament to this as is the attached news article. Happy reading. http://www.azooptics.com/details.asp?newsID=6302
If you look at past comments, people who bought into this at the early prices of around 7p are expecting this to reach over a £1 over the coming 12 months. 2010 is tipped as the year when 3D technology will hit mainstream entertainment.
does anyone know results date for ddd and also why sudden drops???
Final Destination: Death Trip 3D has been confirmed for release August 14th 2009. This fourth instalment in the incredible supernatural thriller has been written by Eric Bress and directed by David R. Ellis. Also one thing that will make this movie very special is the fact that it is being shot in High-Definition 3-D, that means that while we sit in the cinema watching this film we will have the full 3 dimensional effects! This is the first film to be commercially produced using such technologies. Final Destination 4: The Death Trip is the fourth presentation in the Final Destination series, and promises to be a treat to watch owing to the High Definition 3 D effects in the film. The movie shall be aired in 3 D theaters all over the world, which in fact has been the cause of much talk amongst movie viewers as well as the final Destination series fans. Slated for a world wide release on the 28 of august, 2009, the movie is promising to be one of the greatest thrillers to have come our way.
LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, is pleased to announce that the LiDCOrapid Monitor, the Company's tool for acute care fluid and drug management, has been chosen as the sole cardiac output monitoring system to be used in OPTIMISE, a government-supported multi-centre trial in the UK, which aims to improve surgical outcomes by optimising cardiovascular management. This trial is believed to be the largest of its type in the world to date and is therefore a significant validation of LiDCO's technology. ......Co-ordinated by Dr Rupert Pearse, consultant and senior lecturer in intensive care medicine at Barts and London NHS Trust, the study is supported by an £850,000 grant from the National Institute for Health Research. Terry O'Brien, Chief Executive Officer of LiDCO, said: "We believe this will be the largest trial on improving outcomes in high-risk surgery conducted in the world to-date. We are delighted that the LIDCOrapid has been chosen to guide the administration of the fluids and heart drugs each patient will need both during the operation and the following six hours during post operative care. We are confident that OPTIMISE will prove to be a landmark trial inin the widespread adoption of surgical optimisation." In a recent BBC interview about this trial, Dr Pearse stated: "This grant will expand research in the field of critical care and apply this approach to our clinical practice, in order to improve results
I know there are some results expected early sept and fairly sure that with the patent award and the high levels of uptake of new 3D technology, there will be good news for al share holders but does anyone know the exact date to expect the results release?
i think this one should riseslowly as we approach results but will rreally gather momentum as the results date gets closer. FDL was doing well but some bad news hit it- someone on here tipped it as well as JSG but JSG dooes look like another solid one- as soon as I've freed up some funds i'll be ploughing into jsg. With regards to LID, because of the diversification and stakes in several markets - not just UK- LID is in a stringer position than its competitors so longer term results may go further than the 30p mark
Agree about the potential for slight bias if they are house broker but still its not in their interests to champion a losing horse plus the investor news yesterday re the wider US market and maiden profits forecast does no lie- think we'll be seeing a lot more from this once it re-enters the top risers again which is either today or tomorrow
finncap website currently under reconstruction but basically they anticipated what has been confirmed in the analyysis, scroll down the chat and more good links from petertee i think. British bulls also has this as a hold - lots of positive indicators for this one
Not sure about the dow- the only way to check is by looking on the web and seeing where the majorityof their holdings are- if strong US base then yes but my gut is this company deals mainly in UK but worth a look. I''m not holding QED so can;t say - my money is on JSG and LID over the next week or two
current financial year. However the accelerated increase in monitor placements will result in an overall increase in installed base. This will have an increasingly net positive effect on recurring revenue through the sale of the high margin, disposable smart cards to be used with the monitors. In addition, Aspect paid an upfront license fee of US$1.15 million. Aspect has also taken on members of LiDCO's U.S. based sales team, which should give an annualized cost reduction of approximately $0.85m. Overall this relationship will reduce vulnerability to both US currency fluctuations and hospital capital budgets, both of which are increasingly reported by the sector as factors influencing trading this year. Terry O'Brien, Chief Executive Officer of LiDCO, said "LiDCO has seen a significant level of commercial activity in the first half of this year, whilst at the same time has strengthened it's balance sheet by both raising £3.1 million of equity financing in May and receiving corporate license fees from both Becton Dickinson and Aspect. The agreement with Aspect is key to significantly increasing our share of the US market and the foundations are now in place for future growth and increasing recurring revenues. LiDCO is on track to deliver a maiden profit in the coming full year."
current financial year. However the accelerated increase in monitor placements will result in an overall increase in installed base. This will have an increasingly net positive effect on recurring revenue through the sale of the high margin, disposable smart cards to be used with the monitors. In addition, Aspect paid an upfront license fee of US$1.15 million. Aspect has also taken on members of LiDCO's U.S. based sales team, which should give an annualized cost reduction of approximately $0.85m. Overall this relationship will reduce vulnerability to both US currency fluctuations and hospital capital budgets, both of which are increasingly reported by the sector as factors influencing trading this year. Terry O'Brien, Chief Executive Officer of LiDCO, said "LiDCO has seen a significant level of commercial activity in the first half of this year, whilst at the same time has strengthened it's balance sheet by both raising £3.1 million of equity financing in May and receiving corporate license fees from both Becton Dickinson and Aspect. The agreement with Aspect is key to significantly increasing our share of the US market and the foundations are now in place for future growth and increasing recurring revenues. LiDCO is on track to deliver a maiden profit in the coming full year."
As I said - doing very nicely and easily over the £1 mark for all tose who held. If anyone is interested- another share tipped to go through the roof is LID- string buy by several brokers - check out british bulls and sharecrazy. Newsflash below if anyone wants too get in early before these start to fly. Pre close trading update 19 August 2009 LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, is pleased to provide an update on trading for the six months ended 31 July 2009. The Company will announce its interim results for this period on 29 October 2009. The Company has shown a strong sales performance during this period and the Board expects revenues to be significantly higher than the first six months of 2008. It anticipates that revenues will remain higher than 2008 for the full year. Against a more challenging environment for capital equipment sales, the Company's revenue growth represents an increase in market share and in particular reflects record disposables sales. In July LiDCO announced it had signed an exclusive distribution agreement for the LiDCOrapid Monitorwith Aspect Medical Systems ("Aspect"), a pioneer and global market leader in monitoring technology for surgery. Aspect has one of the biggest anaesthesia medical product sales teams in the US and the partnership has given LiDCO full access to the to the US anaesthesia and surgery markets. Since the agreement was completed Aspect has taken stocks of the Li
Pre close trading update 19 August 2009 LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, is pleased to provide an update on trading for the six months ended 31 July 2009. The Company will announce its interim results for this period on 29 October 2009. The Company has shown a strong sales performance during this period and the Board expects revenues to be significantly higher than the first six months of 2008. It anticipates that revenues will remain higher than 2008 for the full year. Against a more challenging environment for capital equipment sales, the Company's revenue growth represents an increase in market share and in particular reflects record disposables sales. In July LiDCO announced it had signed an exclusive distribution agreement for the LiDCOrapid Monitorwith Aspect Medical Systems ("Aspect"), a pioneer and global market leader in monitoring technology for surgery. Aspect has one of the biggest anaesthesia medical product sales teams in the US and the partnership has given LiDCO full access to the to the US anaesthesia and surgery markets. Since the agreement was completed Aspect has taken stocks of the LiDCOrapid products and has already started marketing the product and servicing LiDCO's existing accounts. The transition to this bigger sales force is expected to result in faster adoption of LiDCOrapid Monitors in the U.S. albeit at a lower margin. The lower margin is expected to have an impact on the loss in the curren